

## Special Issue

# Lymphoma and Cancer Therapy

### Message from the Guest Editor

Lymphoproliferative neoplasms represent a large spectrum of diseases, whose etiopathogenesis, clinical features, and treatment is very differentiated. In the meanwhile, we observe more frequent histotypes for which we dispose of standard therapies, as well as more rare histopathological and molecular entities, also recently identified, for which the best treatment options are in definition within clinical trials. In this Special Issue, we aim to collect the results from clinical trials, cohort studies, case reports and reviews, on the innovative therapeutic approaches for lymphomas. We would mostly focus on rare histotypes, for example peripheral T-cell lymphomas, mantle cell lymphoma or extra-nodal lymphomas, and on forms for which the treatment is chosen based on genetic or epigenetic profiles.

### Guest Editor

Dr. Carla Minoia

Hematology Unit-Istituto Tumori "Giovanni Paolo II", Bari, Italy

### Deadline for manuscript submissions

closed (15 July 2022)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/53241](https://mdpi.com/si/53241)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).